CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 718 enrolled
Drug / intervention
ECF843 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04391894
NCT04391894Phase 2Completed

A Randomized, Double-masked, Multicenter Study to Evaluate the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Novartis Pharmaceuticals·interventional·Posted May 18, 2020·Updated Jan 28, 2025

In Brief

A Phase 2 clinical trial evaluating ECF843 and ECF843 vehicle for Dry Eye. Completed, enrolled 718 participants across 52 sites.

Detailed Summary

The study was planned to be conducted in 2 parts: Part 1 to determine the efficacy and safety of ECF843 vs vehicle, followed by Part 2 with additional exploratory assessments of ECF843 vs Vehicle. Both parts of the study included a double-masked study design, with randomization stratified for subjects with Sjogren's Syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 18, 2020
Enrollment StartOct 6, 2020
Primary CompletionMay 13, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.1 years ago

Interventions

ECF843drug

Topical ocular eye drop

ECF843 vehicleother

Topical ocular eye drop